BioCryst Pharmaceuticals Inc (NAS:BCRX)
$ 7.78 0.11 (1.43%) Market Cap: 1.61 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 78/100

BioCryst Pharmaceuticals Inc Corporate Call - 9930 Sept 2020 Data Update Transcript

Sep 30, 2020 / 12:30PM GMT
Release Date Price: $3.44 (-10.43%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the BioCryst conference call. (Operator Instructions) Please be advised that today's conference may be recorded. I'd now like to hand the conference over to your speaker today, John Bluth at BioCryst. Please go ahead.

John D. Bluth
BioCryst Pharmaceuticals, Inc. - SVP of IR & Corporate Communications

Thanks very much, Liz. Good morning, and welcome to BioCryst conference call to provide a data update from our ongoing dose-ranging study in treatment-naïve PNH patients using monotherapy with our oral Factor D inhibitor, BCX9930. Today's press release and slides are available on our website.

Participating with me today are CEO, Jon Stonehouse; Chief Medical Officer, Dr. Bill Sheridan; and Dr. Andrew McDonald, the leading clinical hematologist from Victoria South Africa who has enrolled several PNH patients in the trial.

Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot